William J. Mclaughlin, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 103 Millbury St, Department Of Gynecology, Auburn, MA 01501 Phone: 508-721-4100 |
News Archive
The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Researchers from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, selected to estimate the cost-effectiveness of the newly approved CAR-T therapies, have found the clinical benefit may justify the expensive price.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
In the light of her research showing that adults with learning disabilities were 58 times more likely to die before the age of 50 than the rest of the population, Professor Sheila Hollins has been appointed by Health Secretary Patricia Hewitt to an independent inquiry into unequal health outcomes for people with learning disabilities.
Boys show signs of Duchenne Muscular Dystrophy (DMD) for 2 ½ years before they obtain a diagnosis and disease-specific treatment, about the same length of delay children have endured for the past 20 years despite advances in genetic testing and treatment.
› Verified 3 days ago